Recent Company News

• 10:09 AM ET Dec 15, 2025
  

  StreetAccount Summary - Private company transactions for the week ended 13-Dec

• 09:58 AM ET Dec 11, 2025
  

  UK MHRA approves SpringWorks' Mirdametinib to treat plexiform neurofibromas in children, adolescents, and adults with neurofibromatosis type 1 (€119.00, +2.70)

• 04:53 PM ET Dec 03, 2025
  

  StreetAccount Sector Summary - Healthcare Post-Market

• 08:53 AM ET Dec 03, 2025
  

  StreetAccount Sector Summary - Healthcare Pre-Market

• 06:13 PM ET Dec 02, 2025
  

  Merck KGaA upgraded to outperform from underperform at BNP Paribas Exane

• 08:33 AM ET Dec 02, 2025
  

  PDS Biotech's request for a Type C Meeting with the FDA has been accepted by the agency; meeting scheduled to occur this month ($0.72, 0.00)

• 02:01 PM ET Nov 24, 2025
  

  StreetAccount Summary - Private Company Weekly Recap - Week of 17-Nov

• 08:07 AM ET Nov 24, 2025
  

  Merck KGaA announces FDA has granted Fast Track designation for cladribine capsules for treatment of rare, chronic autoimmune neuromuscular disorder, generalized Myasthenia Gravis (€112.45, +0.15)

• 05:04 PM ET Nov 21, 2025
  

  StreetAccount Sector Summary - Real Estate Weekly Recap

• 04:22 PM ET Nov 20, 2025
  

  StreetAccount Sector Summary - Real Estate Post Market